243 related articles for article (PubMed ID: 26800211)
21. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
[TBL] [Abstract][Full Text] [Related]
22. [Tartrate resistant acid phosphatase--TRACP-5b as a modern bone resorption marker].
Nowak Z; Konieczna M; Saracyn M; Wańkowicz Z
Pol Merkur Lekarski; 2008 Apr; 24(142):351-4. PubMed ID: 18634372
[TBL] [Abstract][Full Text] [Related]
23. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
24. Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese.
Cheng T; Wang M; Chen Z; Eisenberg RA; Zhang Y; Zou Y; Deng Y; Wang M; Zhou L
Chin Med J (Engl); 2014; 127(16):2894-9. PubMed ID: 25131223
[TBL] [Abstract][Full Text] [Related]
25. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis.
Janckila AJ; Neustadt DH; Nakasato YR; Halleen JM; Hentunen T; Yam LT
Clin Chim Acta; 2002 Jun; 320(1-2):49-58. PubMed ID: 11983200
[TBL] [Abstract][Full Text] [Related]
26. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
27. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
[TBL] [Abstract][Full Text] [Related]
28. Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium.
Ylipahkala H; Halleen JM; Kaija H; Vihko P; Väänänen HK
Biochem Biophys Res Commun; 2003 Aug; 308(2):320-4. PubMed ID: 12901871
[TBL] [Abstract][Full Text] [Related]
29. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
[TBL] [Abstract][Full Text] [Related]
30. Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.
Wu YY; Janckila AJ; Ku CH; Yu CP; Yu JC; Lee SH; Liu HY; Yam LT; Chao TY
BMC Cancer; 2010 Apr; 10():158. PubMed ID: 20416078
[TBL] [Abstract][Full Text] [Related]
31. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay.
Wu Y; Lee JW; Uy L; Abosaleem B; Gunn H; Ma M; DeSilva B
J Pharm Biomed Anal; 2009 Jul; 49(5):1203-12. PubMed ID: 19356879
[TBL] [Abstract][Full Text] [Related]
32. Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a.
Chao TY; Lee SH; Chen MM; Neustadt DH; Chaudhry UA; Yam LT; Janckila AJ
Clin Chim Acta; 2005 Sep; 359(1-2):132-40. PubMed ID: 15993395
[TBL] [Abstract][Full Text] [Related]
33. Specificity and clinical performance of two commercial TRACP 5b immunoassays.
Ylipahkala H; Fagerlund KM; Janckila AJ; Houston B; Laurie D; Halleen JM
Clin Lab; 2009; 55(5-6):223-8. PubMed ID: 19728556
[TBL] [Abstract][Full Text] [Related]
34. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
Chu P; Chao TY; Lin YF; Janckila AJ; Yam LT
Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
[TBL] [Abstract][Full Text] [Related]
35. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
36. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
37. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity.
Janckila AJ; Takahashi K; Sun SZ; Yam LT
Clin Chem; 2001 Jan; 47(1):74-80. PubMed ID: 11148180
[TBL] [Abstract][Full Text] [Related]
38. Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects.
Nishizawa Y; Inaba M; Ishii M; Yamashita H; Miki T; Goto H; Yamada S; Chaki O; Kurasawa K; Mochizuki Y
J Bone Miner Metab; 2008; 26(3):265-70. PubMed ID: 18470668
[TBL] [Abstract][Full Text] [Related]
39. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
[TBL] [Abstract][Full Text] [Related]
40. Increased osteoclast activity is associated with aggressiveness of osteosarcoma.
Avnet S; Longhi A; Salerno M; Halleen JM; Perut F; Granchi D; Ferrari S; Bertoni F; Giunti A; Baldini N
Int J Oncol; 2008 Dec; 33(6):1231-8. PubMed ID: 19020756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
